These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12804635)

  • 1. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan.
    Shimamoto T; Tohyama K; Okamoto T; Uchiyama T; Mori H; Tomonaga M; Asano Y; Niho Y; Teramura M; Mizoguchi H; Omine M; Ohyashiki K
    Leuk Res; 2003 Sep; 27(9):783-8. PubMed ID: 12804635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cyclosporine A based therapy for myelodysplastic syndrome].
    Li ZL; Gong M; Xu SH; Huang FZ; Chen YR; Ma YG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):867-70. PubMed ID: 16277860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide for the treatment of patients with myelodysplastic syndromes.
    Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
    Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of myelodysplastic syndrome with cyclosporin A.
    Chen S; Jiang B; Da W; Gong M; Guan M
    Int J Hematol; 2007 Jan; 85(1):11-7. PubMed ID: 17261496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome.
    Itoh M; Yago K; Shimada H; Tohyama K
    Int J Hematol; 2002 Apr; 75(3):302-4. PubMed ID: 11999360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Curative effects of cyclosporin A therapy upon myelodysplastic syndrome].
    Chen SC; Jiang B; Da WM; Gong M; Guan M
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2711-5. PubMed ID: 17199984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
    Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of cyclosporine A in myelodysplastic syndrome--review].
    Guan M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):678-80. PubMed ID: 14706160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Schouten HC; Vellenga E; van Rhenen DJ; de Wolf JT; Coppens PJ; Blijham GH
    Leukemia; 1991 May; 5(5):432-6. PubMed ID: 2033964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.
    Haider M; Al Ali N; Padron E; Epling-Burnette P; Lancet J; List A; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S44-8. PubMed ID: 27521323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive treatments for myelodysplastic syndromes.
    Shimamoto T; Ohyashiki K
    Leuk Lymphoma; 2003 Apr; 44(4):593-604. PubMed ID: 12769335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
    Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
    Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cyclosporine A in combination with thalidomide for the treatment of patients with myelodysplastic syndromes].
    Xu ZF; Qin TJ; Zhang Y; Liu KQ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):451-5. PubMed ID: 21122398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long- term outcome of thalidomide and cyclosporine in patients with IPSS low/intermediate- 1 myelodysplastic syndromes].
    Wang J; Qin T; Xu Z; Zhang Y; Zhang H; Fang L; Pan L; Hu N; Qu S; Li B; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2015 Nov; 36(11):942-6. PubMed ID: 26632468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A preliminary report on treatment of myelodysplastic syndrome with cyclosporin a and androgen].
    Wang JW; Ning F; Liu XD; Lou JX; Chen P; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):855-7. PubMed ID: 15631678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response.
    Ishikawa T; Tohyama K; Nakao S; Yoshida Y; Teramura M; Motoji T; Takatoku M; Kurokawa M; Mitani K; Uchiyama T; Omine M
    Int J Hematol; 2007 Aug; 86(2):150-7. PubMed ID: 17875530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes.
    Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P
    Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hematologic response predictor factors in adults with myelodysplastic syndromes (SMD) treated with cyclosporin A (CSA)].
    Zamora-Pérez E; López-Karpovitch X
    Gac Med Mex; 2015; 151(3):345-53. PubMed ID: 26089271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.
    Platzbecker U; Haase M; Herbst R; Hänel A; Voigtmann K; Thiede CH; Mohr B; Schleyer E; Leopold T; Orth M; Hänel M; Ehninger G; Bornhäuser M
    Br J Haematol; 2005 Mar; 128(5):625-30. PubMed ID: 15725083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.